More reasons to use FARXIGA for management of DMT2 in elderly.

Dear Doctor DORODNY,

In adults with heart failure (NYHA class II-IV) with reduced ejection fraction (HFrEF) with or without type 2 diabetes, FARXIGA is now indicated to reduce the risk of cardiovascular death and hospitalization for heart failure.

With this new indication, FARXIGA is the FIRST and ONLY SGLT2i with FDA approvals across the heart failure risk continuum1-4:

• to help prevent hospitalization for heart failure in patients with type 2 diabetes and multiple cardiovascular risk factors or eCVD • to treat HFrEF patients, with or without type 2 diabetes, by reducing the risk of cardiovascular death and hospitalization for heart failure

Of course, FARXIGA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. But for your patients with type 2 diabetes and multiple cardiovascular risk factors or eCVD, it’s important to consider the role that early treatment with FARXIGA TODAY may play in helping reduce the risk of hospitalization for heart failure TOMORROW.

FARXIGA is not recommended for patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.

eCVD=established cardiovascular disease; FDA=US Food and Drug Administration; NYHA=New York Heart Association; SGLT2i=sodium-glucose cotransporter 2 inhibitor.